An international team based in Austria has unearthed a previously unknown type of virus in samples of human bodily fluids. The researchers were looking for viruses that infect bacteria – known as bacteriophages – with […]
Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced positive preliminary results from recently completed animal studies in its immuno-oncology program, wherein anti-tumor activity was […]
Deerland Probiotics & Enzymes, a US-based supplier of science-backed solutions for microbiome health, announced today its acquisition of Bifodan A/S. Bifodan, based in Hundested, Denmark, is a life science company specialized in developing, manufacturing and […]
The “Million Microbiome of Humans Project” (MMHP) was officially launched at the 14th International Conference on Genomics (ICG-14). Scientists from China, Sweden, Denmark, France, Latvia and other countries will cooperate in microbial metagenomic research, aiming […]
Enterome, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the key functional and molecular interactions between the gut microbiome and the human body to develop targeted therapeutics, has entered into a research collaboration with […]
OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection and stabilization devices, today announced that it has entered into a definitive agreement to acquire the outstanding equity of Diversigen […]
A study in humans and mice demonstrated that a fetus has its own microbiome, or communities of bacteria living in the gut, which are known to play important roles in the immune system and metabolism. […]
Chardan Healthcare Acquisition Corp. (NYSE: CHAC), a special purpose acquisition company sponsored by affiliates of Chardan Capital Markets LLC (“Chardan”), announced today the closing of its merger with BiomX Ltd. (“BiomX”) a microbiome company developing […]
Arranta Bio (“Arranta”) announced the completion of an $82 million funding round and a strategic partnership with Thermo Fisher Scientific. Formed in May 2019, Arranta’s goal is to be the best-in-class microbiome contract development and […]
Many individuals living with chronic disease—whether it’s asthma, allergies, atopic dermatitis, type 2 diabetes, or another condition—readily confirm their therapeutic options leave a lot to be desired. Even if an existing drug product deals adequately […]
A new study presented at UEG Week 2019 has found that 18 commonly used drug categories extensively affect the taxonomic structure and metabolic potential of the gut microbiome. Eight different categories of drugs were also […]